From Verus to Meritage: A Biotech Prototype for Tough Economic Times
This article was originally published in Start Up
Executive Summary
Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.
You may also be interested in...
Meritage Weighs Its Options As It Looks Toward Phase III
Meritage Pharma announced Phase II results of its EoE drug, with hopes of being the first to market in the indication.
Meritage Weighs Its Options As It Looks Toward Phase III
Meritage Pharma announced Phase II results of its EoE drug, with hopes of being the first to market in the indication.
Safety Problems Help AstraZeneca Win Suit Brought By Former Partner Verus
AstraZeneca is in a strange position for a pharmaceutical company: It has benefited in court because of safety problems observed in one of its products